Abstract
Etoricoxib (Arcoxia) is a novel non steroidal anti-inflammatory drug (NSAID) that selectively inhibits the inducible form of cyclo-oxygenase (COX), COX-2. Etoricoxib has a higher COX-1/COX-2 selectivity ratio than the other COX-2-selective NSAIDs as rofecoxib, valdecoxib or celecoxib. Tablets of 60, 90 and 120 mg are available. The recommended dosage of etoricoxib is 60 mg/day for osteoarthritis, 90 mg/day for rheumatoid arthritis and 120 mg/day for acute gouty arthritis. Etoricoxib's efficacy has been widely studied in comparative studies, showing the same efficacy as non-COX-2 selective NSAID, with fewer gastro-intestinal adverse effects.
MeSH terms
-
Administration, Oral
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Arthritis, Gouty / drug therapy*
-
Arthritis, Rheumatoid / drug therapy*
-
Cyclooxygenase 2
-
Etoricoxib
-
Humans
-
Isoenzymes / antagonists & inhibitors
-
Membrane Proteins
-
Osteoarthritis / drug therapy*
-
Prostaglandin-Endoperoxide Synthases
-
Pyridines / administration & dosage
-
Pyridines / adverse effects
-
Pyridines / therapeutic use*
-
Sulfones / administration & dosage
-
Sulfones / adverse effects
-
Sulfones / therapeutic use*
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Isoenzymes
-
Membrane Proteins
-
Pyridines
-
Sulfones
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Prostaglandin-Endoperoxide Synthases
-
Etoricoxib